- In November 2021, Theramex obtained the Femarelle product license to treat menopause symptoms. These products, which are used to balance estrogen levels in women from perimenopause through menopause to post-menopause, are designed to relieve symptoms and conditions that can overlap with adenomyosis symptoms. This move underscores Theramex's dedication to delivering innovative, reliable women's health solutions.
- In October 2021, Bayer AG initiated the phase III clinical program OASIS for its investigational drug for symptomatic uterine fibroids, which often co-exist with adenomyosis. This program highlights Bayer's commitment to developing cutting-edge therapies that address common gynecological conditions, ensuring greater relief and improved quality of life for women. While not directly for adenomyosis, advancements in related conditions often benefit the adenomyosis treatment landscape.
